Document Detail


Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma.
MedLine Citation:
PMID:  9307718     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Adenoid cystic carcinoma is a relatively rare tumour which arises in the parotid and submandibular salivary glands. Initial management is surgical, often with post-operative radiotherapy, but local relapse is common and distant metastasis not infrequent. Chemotherapy is generally reserved for cases where symptoms are not controlled by other means, since the tumour is slow growing and the response rate frequently disappointing. Cisplatin and 5-fluorouracil (5-FU) both show single agent activity in this disease but had not been previously investigated in combination. All patients referred for palliative chemotherapy of metastatic, symptomatic, histologically confirmed adenoid cystic carcinoma between November 1990 and February 1994 were considered for this study. The drugs were administered as follows: cisplatin 100 mg/m2 with appropriate pre- and post-hydration and 5-FU on a 4-day schedule of 1 g/m2/day. A total of 11 patients (7 male, 4 female) with median age 53 years (range 34-69) received 46 courses of chemotherapy (median four, range one to six). All patients had prior surgery and 8 had previously received radiotherapy. There were no objective responses of > 50% reduction in tumour size. 3 patients had a minor response and two progressed on treatment. The symptomatic response rate, however, was 64%, which compares favourably with other previously reported regimens. Toxicity was manageable. The median time to tumour progression was 9 months (range 0-38) and median survival was 12 months (range 1-65). This cisplatin/5-FU regimen would appear to produce a low rate of objective response but useful palliative benefits in advanced symptomatic adenoid cystic carcinoma. Prior series suggest that a higher objective response rate may be possible with a platinum/anthracycline/fluorouracil combination, and investigation of such a regimen is warranted.
Authors:
M E Hill; D O Constenla; R P A'Hern; J M Henk; P Rhys-Evans; N Breach; D Archer; M E Gore
Related Documents :
2553648 - The treatment of advanced juvenile nasopharyngeal angiofibroma.
23604468 - Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk ...
18299238 - Treatment outcomes in squamous cell carcinoma of the maxillary alveolus and palate: a p...
8888258 - Postsurgical recurrent carcinoma of the cervix: reassessment and results of radiation t...
15568338 - Field and semifield evaluation of impacts of transgenic canola pollen on survival and d...
22486898 - Expression of ca-ix is associated with advanced stage tumors and poor survival in oral ...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article    
Journal Detail:
Title:  Oral oncology     Volume:  33     ISSN:  1368-8375     ISO Abbreviation:  Oral Oncol.     Publication Date:  1997 Jul 
Date Detail:
Created Date:  1997-10-14     Completed Date:  1997-10-14     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  9709118     Medline TA:  Oral Oncol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  275-8     Citation Subset:  IM    
Affiliation:
Head and Neck Unit, Royal Marsden NHS Trust, London, U.K.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Carcinoma, Adenoid Cystic / drug therapy*,  secondary*
Cisplatin / administration & dosage,  adverse effects
Female
Fluorouracil / administration & dosage,  adverse effects
Head and Neck Neoplasms / pathology*
Humans
Male
Middle Aged
Palliative Care / methods*
Salivary Gland Neoplasms / pathology
Treatment Outcome
Chemical
Reg. No./Substance:
15663-27-1/Cisplatin; 51-21-8/Fluorouracil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  All-trans retinoic acid induced gene expression and growth inhibition in head and neck cancer cell l...
Next Document:  Verruciform xanthoma of the oral mucosa: an immunohistochemical and ultrastructural study of two cas...